M. Scot Roberts
Known title: Chief Scientific OfficerCIK: 0001705905
Associated companies
Transaction History
| ALT | ▲ Buy | Grant | 875 | $2K | 7/31/2026 | View on chart |
| ALT | ▲ Buy | Option Exercise | 7,775 | $0 | 2/2/2026 | View on chart |
| ALT | ▼ Sell | Tax Withholding | 2,329 | $13K | 2/2/2026 | View on chart |
| ALT | ▲ Buy | Grant | 5,567 | $17K | 1/31/2026 | View on chart |
| ALT | ▼ Sell | Tax Withholding | 2,859 | $16K | 1/30/2026 | View on chart |
| ALT | ▲ Buy | Option Exercise | 9,275 | $0 | 1/30/2026 | View on chart |
| ALT | ▲ Buy | Option Exercise | 15,850 | $0 | 1/27/2026 | View on chart |
| ALT | ▼ Sell | Tax Withholding | 4,748 | $29K | 1/27/2026 | View on chart |
| ALT | ▲ Buy | Option Exercise | 14,600 | $0 | 1/25/2026 | View on chart |
| ALT | ▼ Sell | Tax Withholding | 4,373 | $24K | 1/25/2026 | View on chart |
| ALT | ▲ Buy | Grant | 846 | $3K | 7/31/2025 | View on chart |
| ALT | ▲ Buy | Option Exercise | 7,775 | $0 | 2/2/2025 | View on chart |
| ALT | ▼ Sell | Tax Withholding | 2,316 | $15K | 2/2/2025 | View on chart |
| ALT | ▲ Buy | Option Exercise | 6,166 | $0 | 2/1/2025 | View on chart |
| ALT | ▼ Sell | Tax Withholding | 1,801 | $12K | 2/1/2025 | View on chart |
| ALT | ▲ Buy | Grant | 3,184 | $16K | 1/31/2025 | View on chart |
| ALT | ▲ Buy | Option Exercise | 9,275 | $0 | 1/30/2025 | View on chart |
| ALT | ▼ Sell | Tax Withholding | 2,709 | $19K | 1/30/2025 | View on chart |
| ALT | ▲ Buy | Option Exercise | 14,600 | $0 | 1/25/2025 | View on chart |
| ALT | ▼ Sell | Tax Withholding | 4,264 | $30K | 1/25/2025 | View on chart |
| ALT | ▲ Buy | Grant | 650 | $4K | 7/31/2024 | View on chart |
| ALT | ▲ Buy | Option Exercise | 7,775 | $0 | 2/2/2024 | View on chart |
| ALT | ▼ Sell | Tax Withholding | 2,330 | $22K | 2/2/2024 | View on chart |
| ALT | ▲ Buy | Option Exercise | 6,166 | $0 | 2/1/2024 | View on chart |
| ALT | ▼ Sell | Tax Withholding | 1,801 | $18K | 2/1/2024 | View on chart |
| ALT | ▲ Buy | Grant | 5,860 | $16K | 1/31/2024 | View on chart |
| ALT | ▲ Buy | Option Exercise | 9,275 | $0 | 1/30/2024 | View on chart |
| ALT | ▼ Sell | Tax Withholding | 2,709 | $27K | 1/30/2024 | View on chart |
| ALT | ▲ Buy | Grant | 568 | $2K | 7/31/2023 | View on chart |
| ALT | ▲ Buy | Option Exercise | 7,775 | $0 | 2/2/2023 | View on chart |
| ALT | ▼ Sell | Tax Withholding | 2,375 | $36K | 2/2/2023 | View on chart |
| ALT | ▲ Buy | Option Exercise | 6,166 | $0 | 2/1/2023 | View on chart |
| ALT | ▼ Sell | Tax Withholding | 2,183 | $30K | 2/1/2023 | View on chart |
| ALT | ▲ Buy | Grant | 1,436 | $15K | 1/31/2023 | View on chart |
| ALT | ▲ Buy | Grant | 732 | $5K | 7/31/2022 | View on chart |
| ALT | ▲ Buy | Option Exercise | 787 | $2K | 7/5/2022 | View on chart |
| ALT | ▼ Sell | Open Market | 10,182 | $122K | 7/5/2022 | View on chart |
| ALT | ▼ Sell | Open Market | 26,982 | $324K | 7/1/2022 | View on chart |
| ALT | ▲ Buy | Option Exercise | 4,019 | $10K | 7/1/2022 | View on chart |
| ALT | ▲ Buy | Option Exercise | 22,963 | $68K | 7/1/2022 | View on chart |
| ALT | ▼ Sell | Open Market | 5,462 | $66K | 6/29/2022 | View on chart |
| ALT | ▲ Buy | Option Exercise | 5,462 | $14K | 6/29/2022 | View on chart |
| ALT | ▲ Buy | Option Exercise | 25,583 | $49K | 6/27/2022 | View on chart |
| ALT | ▲ Buy | Option Exercise | 11,769 | $31K | 6/27/2022 | View on chart |
| ALT | ▼ Sell | Open Market | 37,352 | $448K | 6/27/2022 | View on chart |
| ALT | ▲ Buy | Option Exercise | 6,166 | $0 | 2/1/2022 | View on chart |
| ALT | ▼ Sell | Tax Withholding | 2,183 | $17K | 2/1/2022 | View on chart |
| ALT | ▲ Buy | Grant | 2,106 | $14K | 1/31/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 7, 2026
Altimmune to attend Wells Fargo healthcare conference
Altimmune has been confirmed as a participant in the Wells Fargo 21st Annual Healthcare Conference. The company joins a roster of healthcare firms presenting at the event, which is a common venue for biopharma companies to engage with investors and outline pipeline progress. No new clinical, regulatory, or financial announcements accompanied the participation news, so the development is a routine scheduling item rather than a fundamental catalyst. As context, the stock has been trading well below the average analyst price target of $17.22, with its 52-week range between $2.56 and $6.44.
Altimmune to attend Wells Fargo healthcare conference. Altimmune has been confirmed as a participant in the Wells Fargo 21st Annual Healthcare Conference. The company joins a roster of healthcare firms presenting at the event, which is a common venue for biopharma companies to engage with investors and outline pipeline progress. No new clinical, regulatory, or financial announcements accompanied the participation news, so the development is a routine scheduling item rather than a fundamental catalyst. As context, the stock has been trading well below the average analyst price target of $17.22, with its 52-week range between $2.56 and $6.44.